https://doi.org/10.4081/monaldi.2021.1856

The milky way

Vol. 91 No. 4 (2021)
Submitted: March 21, 2021
Accepted: May 20, 2021
Published: July 21, 2021
Chylothorax, Superior vena cava syndrome, pleural effusion
Abstract Views: 445
PDF: 201
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Matteo Daverio
https://orcid.org/0000-0002-8609-3724
Respiratory disease Unit, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Italy.
Mariaenrica Tine'
mariaenrica.tine@gmail.com
https://orcid.org/0000-0002-3094-5721
Respiratory disease Unit, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Italy.
Paolo Spagnolo
Respiratory disease Unit, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Italy.

Mediastinal masses may present with signs and symptoms due to either compression of mediastinal structures or systemic effects of the underlying disease. The present case highlights the advantages of interventional pulmonology in the diagnosis of lymphoma as a cause of chylothorax and superior vena cava syndrome.

 

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
Rice TW, Rodriguez RM, Light RW. The superior vena cava syndrome: Clinical characteristics and evolving etiology. Medicine 2006;85:37–42. DOI: https://doi.org/10.1097/01.md.0000198474.99876.f0
McGrath EE, Blades Z, Anderson PB. Chylothorax: Aetiology, diagnosis and therapeutic options. Respir Med 2010;104:1–8. DOI: https://doi.org/10.1016/j.rmed.2009.08.010
Rahman NM, Chapman SJ, Davies RJO. Pleural effusion: A structured approach to care. Br Med Bull 2004;72:31–47. DOI: https://doi.org/10.1093/bmb/ldh040
Maldonado F, Hawkins FJ, Daniels CE et al. Pleural fluid characteristics of chylothorax. Mayo Clin Proc 2009;84:129–33. DOI: https://doi.org/10.4065/84.2.129
Staats BA, Ellefson RD, Budahn LL, et al. The lipoprotein profile of chylous and nonchylous pleural effusions. Mayo Clin Proc 1980;55:700-4.
O’callaghan AM, Mead GM. Chylothorax in lymphoma: Mechanisms and management. Ann Oncol 1995;6:603–8. DOI: https://doi.org/10.1093/oxfordjournals.annonc.a059251
Mares DC, Mathur PN. Medical thoracoscopic talc pleurodesis for chylothorax due to lymphoma: A case series. Chest 1998;114:731–5. DOI: https://doi.org/10.1378/chest.114.3.731
Gandotra S, Dotson T, Lamar Z, er al. Endobronchial Ultrasound transbronchial needle aspiration for the diagnosis of lymphoma. J Bronchol Interv Pulmonol 2018;25:97–102. DOI: https://doi.org/10.1097/LBR.0000000000000449
Lim CE, Steinfort DP, Irving LB. Diagnostic performance of 19-gauge endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) in suspected lymphoma: A prospective cohort study. Clin Respir J 2020;14:800–5. DOI: https://doi.org/10.1111/crj.13198
Labarca G, Sierra-Ruiz M, Kheir F et al. Diagnostic accuracy of endobronchial ultrasound transbronchial needle aspiration in lymphoma a systematic review and meta-analysis. Ann Am Thor Soc 2019;16:1432–9. DOI: https://doi.org/10.1513/AnnalsATS.201902-175OC
Vitolo U, Seymour JF, Martelli M et al. Extranodal diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016;27:91–102. DOI: https://doi.org/10.1093/annonc/mdw175

How to Cite

Daverio, Matteo, Mariaenrica Tine’, and Paolo Spagnolo. 2021. “The Milky Way”. Monaldi Archives for Chest Disease 91 (4). https://doi.org/10.4081/monaldi.2021.1856.
Copyright (c) 2021 The Author(s) Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.